Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study

PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced positive efficacy results from the 90-day challenge studies of its single-dose oral cholera vaccine candidate, PXVX0200, which utilizes the same attenuated vaccine strain previously approved and marketed in several countries under the …

Source: finance.yahoo.com

Leave a Reply